Literature DB >> 23152403

Cytochrome P450 2B6: function, genetics, and clinical relevance.

Miia Turpeinen1, Ulrich M Zanger.   

Abstract

Cytochrome P450 (CYP) 2B6 belongs to the set of important hepatic drug-metabolizing CYPs. It makes up roughly 3%-6% of total hepatic CYP content and metabolizes several pharmaceuticals including bupropion, efavirenz, cyclophosphamide, pethidine, ketamine and propofol. The enzyme is susceptible to drug-drug interactions by enzyme induction and inhibition. In addition to drugs, CYP2B6 is able to both detoxify and bioactivate a number of procarcinogens and environmental agents including pesticides and herbicides. There is an extensive interindividual variability in the expression of CYP2B6, which is in part explained by extensive genetic polymorphism. CYP2B6 is one of the most polymorphic CYP genes in humans with over 100 described SNPs, numerous complex haplotypes and distinct ethnic and racial frequencies. This review summarizes the basic properties of CYP2B6 and the main characteristics of clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152403     DOI: 10.1515/dmdi-2012-0027

Source DB:  PubMed          Journal:  Drug Metabol Drug Interact        ISSN: 0792-5077


  35 in total

1.  Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.

Authors:  Doo-Yeoun Cho; Joan H Q Shen; Suzanne M Lemler; Todd C Skaar; Lang Li; Julia Blievernicht; Ulrich M Zanger; Kwon-Bok Kim; Jae-Gook Shin; David A Flockhart; Zeruesenay Desta
Journal:  Drug Metab Pharmacokinet       Date:  2015-07-29       Impact factor: 3.614

2.  Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.

Authors:  Jianjun Cheng; Patrick M Giguère; Oluseye K Onajole; Wei Lv; Arsen Gaisin; Hendra Gunosewoyo; Claire M Schmerberg; Vladimir M Pogorelov; Ramona M Rodriguiz; Giulio Vistoli; William C Wetsel; Bryan L Roth; Alan P Kozikowski
Journal:  J Med Chem       Date:  2015-02-10       Impact factor: 7.446

3.  Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.

Authors:  Zeruesenay Desta; Ingrid F Metzger; Nancy Thong; Jessica B L Lu; John T Callaghan; Todd C Skaar; David A Flockhart; Raymond E Galinsky
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

4.  Characterization of CYP2B6 in a CYP2B6-humanized mouse model: inducibility in the liver by phenobarbital and dexamethasone and role in nicotine metabolism in vivo.

Authors:  Zhihua Liu; Lei Li; Hong Wu; Jing Hu; Jun Ma; Qing-Yu Zhang; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2014-11-19       Impact factor: 3.922

5.  Differences in Methadone Metabolism by CYP2B6 Variants.

Authors:  Sarah Gadel; Christina Friedel; Evan D Kharasch
Journal:  Drug Metab Dispos       Date:  2015-04-20       Impact factor: 3.922

6.  Inhibition of cytochrome P450 2B6 by Astragalus extract mixture HT042.

Authors:  Harim Kim; Yejin Lee; Vitchan Kim; Rowoon Lee; Soo Kyung Bae; Mi-Kyoung Kwak; Sung Hoon Lee; Donghak Kim
Journal:  Toxicol Res       Date:  2019-12-04

7.  Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Lizanne de Kock; Sherwin K B Sy; Bernd Rosenkranz; Andreas H Diacon; Kim Prescott; Kenneth R Hernandez; Mingming Yu; Hartmut Derendorf; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

8.  Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.

Authors:  Sarah Gadel; Amanda Crafford; Karen Regina; Evan D Kharasch
Journal:  Drug Metab Dispos       Date:  2013-01-08       Impact factor: 3.922

Review 9.  Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.

Authors:  Panjasaram Naidoo; Vasudevan V Chetty; Manoranjenni Chetty
Journal:  Eur J Clin Pharmacol       Date:  2014-01-05       Impact factor: 2.953

10.  Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.

Authors:  Evan D Kharasch; Karen J Regina; Jane Blood; Christina Friedel
Journal:  Anesthesiology       Date:  2015-11       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.